Leading Clinicians in the Field of Antibiotics and Infectious Disease
Our clinical advisors are instrumental in formulating our research and development and commercialization strategy.
Paul Ambrose, PharmD
Paul G. Ambrose is President of the Institute for Clinical Pharmacodynamics (ICPD), Latham, New York, USA. He is also an Honorary Research Fellow in Infectious Diseases at the University of Oxford, Oxford, UK and Adjunct Associate Research Professor at the University at Buffalo, Buffalo, New York.
Dr. Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained though the use of non-clinical (in vitro and animal) PK-PD infection models may be leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities. ICPD has successfully utilized this approach for support of regulatory decision-making and as support for Clinical and Laboratory Standards Institute susceptibility breakpoint determinations.
Dr. Ambrose is a member of the working group on ‘Skin and Skin Structure Infection-Community-Acquired Pneumonia’ for The Biomarkers Consortium at the National Institutes of Health, Bethesda, Maryland, USA and is a member of the ‘ReAct: Action on Antibiotic Resistance’ Working Group in Uppsala, Sweden.
He is Editor of Antimicrobial Agents Chemotherapy and an Editorial Board Member of the Journal of Infectious Disease Pharmacotherapy. Dr. Ambrose is the author of over 105 peer-reviewed scientific publications and approximately 150 scientific abstracts. Dr. Ambrose has served as an Editor for four textbooks; most notably the 1st and 2nd Editions of Antimicrobial Pharmacodynamics in Theory and Clinical Practice.
Gordon Archer, MD
Dr. Archer graduated from medical school at the University of Virginia and completed his internship, residency and fellowship in Infectious Diseases at the University of Michigan. He joined the faculty at the Medical College of Virginia (now the Virginia Commonwealth University School of Medicine) in 1975 and has been there for his entire career.
His early research interest was in infective endocarditis and he was one of the first developers and users of the rabbit model of endocarditis. In particular, he was interested in prosthetic valve endocarditis caused by coagulase-negative staphylococci. His research evolved to a study of staphylococci and, specifically, to antimicrobial resistance in staphylococci with a focus on antibiotic resistance gene exchange and plasmid biology. He has been continuously NIH-funded for his research since 1975, including an NIH MERIT grant from 1995 to 2005. He has been the Senior Associate Dean for Research and Research Training in the VCU School of Medicine since 2005 which includes directing both the MD-PhD combined degree and the PhD predoctoral programs. He has consulted for and been on the Scientific Advisory Board of a number of pharmaceutical companies including, most recently, Achillion and Cubist Pharmaceuticals and from 1998 to 2003 was the recipient of a Bristol Myers Squibb unrestricted research grant. He was a member of and then Chair of the NIH BM1 and DDR Study Sections and is currently on the Scientific Working Group for the Network on Antimicrobial Resistance in Staphylococci (NARSA). He is on the Editorial Board of the ASM journal, Antimicrobial Agents and Chemotherapy.
Helen W. Boucher, MD, FIDSA, FACP
Helen Boucher is director of the infectious diseases fellowship program, staff physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and associate professor of medicine at Tufts University School of Medicine in Boston, Massachusetts.
Dr. Boucher received her medical degree from the University of Texas Medical School at Houston. She completed her internship, residency and Chief Residency in Internal Medicine at the New England Deaconess Hospital and her clinical and research fellowships in infectious diseases at the Beth Israel Deaconess Medical Center. Dr. Boucher is board certified in internal medicine and Infectious diseases.
Dr. Boucher’s clinical interests include infections in immunocompromised patients with an emphasis on transplant-related bacterial and fungal infections and human immunodeficiency virus as well as S. aureus infections. Her research interests focus on S. aureus and the development of new anti-infective agents. She is the author or coauthor of numerous abstracts, chapters and peer-reviewed articles, which have been published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and Drugs.
Dr. Boucher is a member of several professional organizations, among them the Infectious Diseases Society of America, the American Society for Microbiology, and the American Medical Association. In 1998, the Massachusetts Infectious Diseases Society awarded Dr. Boucher the Edward H. Kass Award for Clinical Excellence. In May 2006, she was elected to the Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) and in October, 2007, she was elected to the Research Committee of the IDSA.
Dr. Boucher was elected a Fellow in the American College of Physicians in 2008. In 2009, she was appointed to the Steering Committee of the Mycoses Study Group. She was included in Best Doctors in America 2009, 2010, 2011, 2012, and 2013. In 2011, Dr. Boucher was elected Fellow and Member of the Board of Directors of the Infectious Diseases Society of America. In 2012, she was elected to the American Board of Internal Medicine Infectious Disease Exam Writing Committee and in 2014, to the American Board of Internal Medicine Infectious Diseases Board.
George L. Drusano, MD
Dr. George L. Drusano is Director of the Institute for Therapeutic Innovation of the University of Florida. After graduating magna cum laude, ΦΒΚ from the Honors Program at Boston College, Dr. Drusano graduated cum laude, ΑΩΑ from the University of Maryland School of Medicine in Baltimore. He completed his medical internship and residency at the University of Maryland Hospital, where he was Chief Medical Resident. He was also a Fellow in Medicine in Infectious Diseases at that institution.
Dr. Drusano is a reviewer for prestigious peer-reviewed journals, including Science-Translational Medicine, New England Journal of Medicine, the Annals of Internal Medicine, Archives of Internal Medicine, American Journal of Medicine, Journal of Infectious Diseases, the Journal of Antimicrobial Chemotherapy, and Antiviral Research. He was also editor of the section of pharmacology and experimental therapeutics for Antimicrobial Agents and Chemotherapy for 10 years. He is currently an Editor for mBio. He is the author of over 300 articles in peer-reviewed journals such as the Journal of Clinical Investigation, Nature Reviews Microbiology, Journal of the American Medical Association, Annals of Internal Medicine, Journal of Infectious Diseases, Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, AIDS, Clinical Pharmacology and Therapeutics, Journal of Clinical Pharmacology, and Diagnostic Microbiology and Infectious Diseases.
Dr. Drusano is a Fellow of the Infectious Diseases Society of America. On the national level, Dr. Drusano was a member of the Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC) Program Committee and the IDSA Program Committee. He has served on multiple National Institute of Allergy and Infectious Diseases (NIAID) Review Groups. He has served as an ad hoc member of NIAID Council on two occasions to support issues regarding emergence of bacterial resistance. He also serves as a consultant to NIAID and CDC on Biodefense issues. In 2010, he was Chair of the Gordon Conference on New Antimicrobial Discovery and Development. He has won a number of awards, including being named Distinguished Investigator of the Year (2003) by the American College of Clinical Pharmacology. He was named recipient of the Maxwell Finland Award for Scientific Achievement for 2012 from the National Foundation for Infectious Diseases. He was named the recipient of the Cubist-ICAAC award for 2013 from the American Society for Microbiology. Most recently, he was awarded the Paul Ehrlich Magic Bullet Award in 2015.
An active researcher, Dr. Drusano has focused on mathematical modeling and the pharmacodynamics of anti-infective chemotherapy, especially the pharmacodynamics of anti-tuberculosis agents, MDR/XDR nosocomial pathogens, multiple anti-viral agents and the therapy of biodefense pathogens. He has been awarded a Program Project Grant from NIAID “Choosing Drug Doses for Biodefense Pathogens”, R01’s from NIAID for “Resistance Suppression for P. aeruginosa using Novel Combination Therapy Modeling”, Optimizing Combination Therapy for Hepatitis C virus with pharmacodynamic models and an R01 for drug development “Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agents”. Most recently, he was awarded a P01 from NIAID “Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis”.
Professor William Hope FRACP, FRCPA, PhD
William Hope (FRACP, FRCPA, PhD) is currently a National Institute of Health Research Clinician Scientist and Professor of Therapeutics and Infectious Diseases at The University of Liverpool in the United Kingdom. Professor Hope is a Fellow of the Royal Australasian College of Physicians and a Fellow of the Royal College of Pathologists of Australasia.
William Hope qualified in Medicine in 1991 before undertaking specialist training in Infectious Diseases and Clinical Microbiology. He completed his PhD in antimicrobial pharmacology in 2006, while undertaking fellowships at The University of Manchester, UK and the National Institutes of Health, Bethesda, USA. He moved to the University of Liverpool in June 2012.
Professor Hope’s areas of special interest and research are antimicrobial pharmacokinetics and pharmacodynamics, mathematical modelling of antimicrobial agents, population pharmacokinetics, and individualisation of antimicrobial therapy. Professor Hope is Scientific Advisor to the ESCMID Fungal Infection Study Group (EFSIG), a member of the ICAAC Program Committee for Antimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology, and Medical Guideline Director for the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).
James B. Kahn, MD, FIDSA
James B. Kahn, M.D., FIDSA is the founder and principal of JBK Strategic Consultations, LLC, a small firm providing Infectious Disease expertise to the Pharmaceutical, Venture Capital, and Medico-legal communities.
He was graduated from Harvard College with a B.A. magna cum laude in Latin American History and Literature and obtained his M.D. degree with honors from Harvard Medical School. After performing an Internal Medicine internship and junior residency at Boston’s Beth Israel Hospital, he served for two years at CDC as an EIS officer with the rank of Lieutenant Commander (Major). He returned to Boston for a year’s senior residency in Internal Medicine at the Beth Israel, then took a two year clinical Infectious Diseases fellowship at the Massachusetts General Hospital. He is Board-certified in both I.M. and I.D..
After 18 years in the solo private practice of I.D. Medicine, during the course of which he founded and was president of the Northern New England Infectious Diseases Society, Dr. Kahn was recruited by Johnson & Johnson’s Ortho-McNeil Pharmaceutical to be the first Director of their new I.D. Franchise. In addition to doing numerous clinical trials for the antimicrobial FLOXIN, he also took over the clinical development of LEVAQUIN and was responsible for the sNDAs that led to 8 new FDA-approved indications. He proposed and then developed the higher-dose, shorter-course approach to accelerate pathogen eradication and reduce anti-bacterial exposure. At the time of his retirement after more than 15 years at J&J, he had authored more than 140 peer-reviewed scientific papers and presentations at major Infectious Disease meetings.
He has been offering his consulting services since leaving Industry in 2007 and continues professional society membership in ASM, IDSA, ESCMID, NNEIDS, RSTMH, and ISID. He attends numerous national and international I.D. meetings and maintains close personal and profession contacts with many US and global opinion leaders.
Keith A. Rodvold, PharmD
Dr. Keith A. Rodvold received his Bachelor of Science in Pharmacy (1978) and Doctor of Pharmacy (1980) degrees from the University of Minnesota. He completed his research fellowship in clinical pharmacokinetics and pharmacology at St. Paul-Ramsey Medical Center and the University of Minnesota (1980-1981) and was a Clinical Pharmacy Specialist at St. Joseph’s Hospital in Marshfield, Wisconsin, from 1981 to 1984. Dr. Rodvold was appointed as an Assistant Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago in 1984, was promoted to the rank of Associate Professor with tenure in 1989, and to the rank of Professor in 1994. In addition, he is also a Professor of Pharmacy in Medicine in the College of Medicine at the University of Illinois at Chicago. Dr. Rodvold conducts research in the area of clinical pharmacokinetics and pharmacodynamics of anti-infective agents, with a focus on drug penetration and disposition in special populations. Dr. Rodvold has authored more than 145 original research and review publications, 40 book chapters, and co-editor of the textbook, Drug Interactions in Infectious Diseases, currently in its third edition. The American College of Clinical Pharmacy presented Dr. Rodvold with the 2003 Russell R. Miller Award in recognition of his sustained and outstanding contributions to the literature of clinical pharmacy. Dr. Rodvold is a former member of the Anti-Infective Drug Advisory Committee and Pediatric Drug Advisory Subcommittee for the Food and Drug Administration. He is an active member of numerous professional societies and has been elected Fellow of the Infectious Diseases Society of America, American College of Clinical Pharmacology, and American College of Clinical Pharmacy.
Contact us to learn about investment opportunities.